NCT01401959 2018-06-15Trial of Eribulin in Patients Who Do Not Achieve Pathologic Complete Response (pCR) Following Neoadjuvant ChemotherapySCRI Development Innovations, LLCPhase 2 Completed127 enrolled 11 charts